search
Back to results

Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. (ToxHD)

Primary Purpose

Hailey-Hailey Disease, Darier Disease

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Botulism Toxin Treatment
Sponsored by
University Hospital, Toulouse
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Hailey-Hailey Disease focused on measuring Botulism Toxin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Confirmed diagnosis (clinical and histological features) of Hailey Hailey or Darier diseases.
  • Moderate to very severe lesions located in large folds
  • Patient aged 18 ans or more
  • Patient with health coverage
  • Patient who have signed the consent form
  • Patient proficient into filling out the questionnaires.

Exclusion Criteria:

  • Hypersensibility to toxin or excipients
  • Myastheny
  • Deglutition's problems
  • Past medical history of dysphagia or aspiration pneumonia
  • Pregnancy (positive B-HCG test performed a maxima 72h before) or breastfeeding
  • Mental , physical incapacity to fill in the questionnaires
  • Guardianship patients
  • Skin infections at the inclusion visit
  • Application in the last 7 days at the site of injection of local treatments (apart emollients or antiseptics) or injections of botulism toxin or dynamic phototherapy or laser in the last 6 months.
  • Systemic treatment with aminosides in the last 15 days
  • Inclusion in another study in the last 2 months.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Botulism Toxin treatment

    Arm Description

    Injection of 50 UI Botulism toxin for the treated zone

    Outcomes

    Primary Outcome Measures

    Evaluation of quality of life measured by change in the DLQI score
    Variation of DLQI score between Baseline and M1

    Secondary Outcome Measures

    Evaluation of quality of life measured by change in the DLQI score
    Variation of DLQI score between Baseline and M3
    Evaluation of quality of life measured by change in the DLQI score
    Variation of DLQI score between Baseline and M6
    Evaluation of skin improvement in treated areas using change the IGA score
    Variation of IGA score between Baseline and M1
    Evaluation of skin improvement in treated areas using change the IGA score
    Variation of IGA score between Baseline and M3
    Evaluation of skin improvement in treated areas using change the IGA score
    Variation of IGA score between Baseline and M6
    Evaluation of psychosocial impairment at measured by change in the HidroQoL score
    Variation of HidroQoL score between Baseline and M1
    Evaluation of psychosocial impairment measured by change in the HidroQoL score
    Variation of HidroQoL score between Baseline and M3
    Evaluation of psychosocial impairment measured by change in the HidroQoL score
    Variation of HidroQoL score between Baseline and M6
    Evaluation by the investigator of the treated lesions global severity change as assessed by comparison using measurement of the affected area
    Variation of treated lesions severity between Baseline and M1
    Evaluation by the investigator of the treated lesions global severity change as assessed by comparison using measurement of the affected area
    Variation of treated lesions severity between Baseline and M3
    Evaluation by the investigator of the treated lesions global severity change as assessed by comparison using measurement of the affected area
    Variation of treated lesions severity between Baseline and M6
    Evaluation of patient's satisfaction Using the IGA score " Improvement Global Assessment "
    Evaluation of patient treatment acceptability using visual analogic pain scale
    Evaluation of acceptability over the medium to long term as assessed by occurence of side effects
    Evaluation of acceptability over the medium to long term as assessed by occurence of side effects
    Evaluation of acceptability over the medium to long term as assessed by occurence of side effects
    Evaluation of long term efficacy as assessed by percentage of non-responder patients with IGA score egal to 0
    Evaluation of long term efficacy as assessed by delay for significant relapse (reappearance of skin lesions justifying treatment)
    Evaluation of long term efficacy as assessed by comparison between the number of infection episodes occurred during the 6 months before the study or during the 6 months of the study

    Full Information

    First Posted
    May 20, 2016
    Last Updated
    November 29, 2021
    Sponsor
    University Hospital, Toulouse
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02782702
    Brief Title
    Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds.
    Acronym
    ToxHD
    Official Title
    Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. Toxin Hailey Darier
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2021
    Overall Recruitment Status
    Completed
    Study Start Date
    September 2015 (undefined)
    Primary Completion Date
    November 2017 (Actual)
    Study Completion Date
    November 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University Hospital, Toulouse

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Hailey Hailey and Darier disease are rare genetic dermatoses. Mutations of 2 genes (ATP2C1 or ATP2A2 respectively) are responsible for the diseases. These genes have a key role in calcium pump; their defect create abnormal link between keratinocytes' desmosomes and induce skin lesions. Clinically, patients present with inflammatory lesions located in the folds. Quality of life is impaired because of pain, pruritus and tendency to infections. Lesions are permanent but acute exacerbations occur in hot seasons because of increased sweating. Usual therapies are often not effective (local treatment, laser, phototherapy). Because sweating is a well established inducing or aggravating factor, botulism toxin could be an effective treatment for these diseases. Botulism toxin is already used in clinical practice and acts via a decreased sweet secretion. Improvement of skin lesions in Hailey-Hailey or Darier diseases has been previously reported in a few cases but there is no study properly evaluating the benefit of such treatment. The aim of the project is to study the improvement of quality of life for patients suffering from Hailey-Hailey or Darier diseases after a injections of botulism toxin in large skin folds. The principal objective is to estimate the distribution of the variation of quality of life at M1 vs. baseline.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hailey-Hailey Disease, Darier Disease
    Keywords
    Botulism Toxin

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Phase 1
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    30 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Botulism Toxin treatment
    Arm Type
    Experimental
    Arm Description
    Injection of 50 UI Botulism toxin for the treated zone
    Intervention Type
    Drug
    Intervention Name(s)
    Botulism Toxin Treatment
    Intervention Description
    Injection of 50 UI of botulism toxin for treated zone
    Primary Outcome Measure Information:
    Title
    Evaluation of quality of life measured by change in the DLQI score
    Description
    Variation of DLQI score between Baseline and M1
    Time Frame
    Day 0 and day 30
    Secondary Outcome Measure Information:
    Title
    Evaluation of quality of life measured by change in the DLQI score
    Description
    Variation of DLQI score between Baseline and M3
    Time Frame
    Day 0 and day 90
    Title
    Evaluation of quality of life measured by change in the DLQI score
    Description
    Variation of DLQI score between Baseline and M6
    Time Frame
    Day 0 and day 180
    Title
    Evaluation of skin improvement in treated areas using change the IGA score
    Description
    Variation of IGA score between Baseline and M1
    Time Frame
    Day 0 and Day 30
    Title
    Evaluation of skin improvement in treated areas using change the IGA score
    Description
    Variation of IGA score between Baseline and M3
    Time Frame
    Day 0 and Day 90
    Title
    Evaluation of skin improvement in treated areas using change the IGA score
    Description
    Variation of IGA score between Baseline and M6
    Time Frame
    Day 0 and Day 180
    Title
    Evaluation of psychosocial impairment at measured by change in the HidroQoL score
    Description
    Variation of HidroQoL score between Baseline and M1
    Time Frame
    Day 0 and Day 30
    Title
    Evaluation of psychosocial impairment measured by change in the HidroQoL score
    Description
    Variation of HidroQoL score between Baseline and M3
    Time Frame
    Day 0 and Day 90
    Title
    Evaluation of psychosocial impairment measured by change in the HidroQoL score
    Description
    Variation of HidroQoL score between Baseline and M6
    Time Frame
    Day 0 and Day 180
    Title
    Evaluation by the investigator of the treated lesions global severity change as assessed by comparison using measurement of the affected area
    Description
    Variation of treated lesions severity between Baseline and M1
    Time Frame
    Day 0 and Day 30
    Title
    Evaluation by the investigator of the treated lesions global severity change as assessed by comparison using measurement of the affected area
    Description
    Variation of treated lesions severity between Baseline and M3
    Time Frame
    Day 0 and Day 90
    Title
    Evaluation by the investigator of the treated lesions global severity change as assessed by comparison using measurement of the affected area
    Description
    Variation of treated lesions severity between Baseline and M6
    Time Frame
    Day 0 and Day 180
    Title
    Evaluation of patient's satisfaction Using the IGA score " Improvement Global Assessment "
    Time Frame
    Day 180
    Title
    Evaluation of patient treatment acceptability using visual analogic pain scale
    Time Frame
    Day 0 after injection
    Title
    Evaluation of acceptability over the medium to long term as assessed by occurence of side effects
    Time Frame
    Day 30
    Title
    Evaluation of acceptability over the medium to long term as assessed by occurence of side effects
    Time Frame
    Day 90
    Title
    Evaluation of acceptability over the medium to long term as assessed by occurence of side effects
    Time Frame
    Day 180
    Title
    Evaluation of long term efficacy as assessed by percentage of non-responder patients with IGA score egal to 0
    Time Frame
    Day 30
    Title
    Evaluation of long term efficacy as assessed by delay for significant relapse (reappearance of skin lesions justifying treatment)
    Time Frame
    Up to 180 days
    Title
    Evaluation of long term efficacy as assessed by comparison between the number of infection episodes occurred during the 6 months before the study or during the 6 months of the study
    Time Frame
    Up to 180 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Confirmed diagnosis (clinical and histological features) of Hailey Hailey or Darier diseases. Moderate to very severe lesions located in large folds Patient aged 18 ans or more Patient with health coverage Patient who have signed the consent form Patient proficient into filling out the questionnaires. Exclusion Criteria: Hypersensibility to toxin or excipients Myastheny Deglutition's problems Past medical history of dysphagia or aspiration pneumonia Pregnancy (positive B-HCG test performed a maxima 72h before) or breastfeeding Mental , physical incapacity to fill in the questionnaires Guardianship patients Skin infections at the inclusion visit Application in the last 7 days at the site of injection of local treatments (apart emollients or antiseptics) or injections of botulism toxin or dynamic phototherapy or laser in the last 6 months. Systemic treatment with aminosides in the last 15 days Inclusion in another study in the last 2 months.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Aude MAZA RIOLAND, MD
    Organizational Affiliation
    University Hospital, Toulouse
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided
    Citations:
    PubMed Identifier
    33602313
    Citation
    Dreyfus I, Maza A, Rodriguez L, Merlos M, Texier H, Rousseau V, Sommet A, Mazereeuw-Hautier J. Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease: an open-label 6-month pilot interventional study. Orphanet J Rare Dis. 2021 Feb 18;16(1):93. doi: 10.1186/s13023-021-01710-x.
    Results Reference
    result

    Learn more about this trial

    Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds.

    We'll reach out to this number within 24 hrs